Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a, Proof-of-Concept, Multicenter, Parallel, Vehicle-Controlled, Double-Masked, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of IVW-1001 Ophthalmic Eyelid Wipe in Subjects With Dry Eye Disease

Next Previous
Trial Profile

Phase 1/2a, Proof-of-Concept, Multicenter, Parallel, Vehicle-Controlled, Double-Masked, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of IVW-1001 Ophthalmic Eyelid Wipe in Subjects With Dry Eye Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IVIEW 1001 (Primary)
  • Indications Dry eyes
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors iView Therapeutics

Most Recent Events

  • 15 Jan 2026 According to an IVIEW Therapeutics media release, the data from the trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held in Denver, Colorado on May 3-7, 2026.
  • 21 Oct 2025 According to an IVIEW Therapeutics media release, key findings from this trial were presented in two recent ReachMD podcast episodes, recorded in conjunction with the American Academy of Ophthalmology (AAO) 2025 Annual Meeting in Orlando, Florida.
  • 01 Oct 2025 According to an IVIEW Therapeutics media release, abstract of this study accepted as an On-Demand Poster at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top